BTI
URGN icon

Blue Trust Inc’s UroGen Pharma URGN Stock Holding History

Blue Trust Inc’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,567
Closed -$16K – 2701
2023
Q3 		$16K Hold
1,567
– – ﹤0.01% 1257
2023
Q2 		$14K Hold
1,567
– – ﹤0.01% 1198
2023
Q1 		$14K Hold
1,567
– – ﹤0.01% 1511
2022
Q4 		$13K Buy
+1,567
New +$14.8K ﹤0.01% 1460
2022
Q3 		– Sell
-670
Closed -$6K – 2335
2022
Q2 		$6K Buy
+670
New +$4.6K ﹤0.01% 1407

Other funds holding URGN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Blue Trust Inc's URGN Position: Q4 2023 in Review

Blue Trust Inc sold out of UroGen Pharma (URGN) in Q4 2023, closing a stake of 1,567 shares — an estimated $16K sold.

Blue Trust Inc first reported a position in URGN in Q2 2022 and held it in 5 quarters. The position peaked at $16K in Q3 2023. 105 funds tracked by Wall St. Rank hold URGN as of Q4 2023.

  • Blue Trust Inc reported no remaining UroGen Pharma position as of Q4 2023 after selling out during the quarter.
  • Blue Trust Inc sold 1,567 UroGen Pharma shares in Q4 2023, an estimated $16K.
  • Blue Trust Inc first reported a position in UroGen Pharma in Q2 2022 and held it in 5 quarters.
  • Blue Trust Inc's UroGen Pharma position peaked at $16K in Q3 2023.
  • 105 funds tracked by Wall St. Rank held UroGen Pharma as of Q4 2023.

Based on Blue Trust Inc's 13F filing for Q4 2023, filed 18 Jan 2024.